Citadel Advisors’s Gain Therapeutics GANX Stock Holding History

Citadel Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.1K	Sell	14,500 -36,900	-72%	-$80.3K	﹤0.01%	12589
2025 Q4	$166K	Buy	51,400 +41,100	+399%	+$110K	﹤0.01%	11207
2025 Q3	$18.2K	Buy	+10,300	New	+$17.4K	﹤0.01%	12507
2025 Q2	–	Sell	-8,400	Closed	-$16K	–	13408
2025 Q1	$16K	Buy	8,400 +2,700	+47%	+$5.99K	﹤0.01%	13296
2024 Q4	$12.3K	Buy	+5,700	New	+$11.4K	﹤0.01%	13508
2024 Q2	–	Sell	-5,600	Closed	-$21.1K	–	14670
2024 Q1	$21.1K	Buy	5,600 +4,100	+273%	+$17K	﹤0.01%	12978
2023 Q4	$4.9K	Sell	1,500 -200	-12%	-$556	﹤0.01%	13473
2023 Q3	$5.49K	Sell	1,700 -15,200	-90%	-$57.6K	﹤0.01%	13388
2023 Q2	$75.7K	Buy	16,900 +4,100	+32%	+$20K	﹤0.01%	11303
2023 Q1	$61.7K	Buy	+12,800	New	+$52.3K	﹤0.01%	11891

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's GANX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Gain Therapeutics (GANX) in Q1 2026: 24,900 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #12413 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in GANX as recently as Q3 2025.

Citadel Advisors first reported a position in GANX in Q4 2021 and has held it in 11 quarters since. The position peaked at $661K in Q3 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Citadel Advisors held 24,900 shares of Gain Therapeutics worth $48.3K as of Q1 2026.
Gain Therapeutics was a new Citadel Advisors position in Q1 2026.
Gain Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12413 holding.
Citadel Advisors first reported a position in Gain Therapeutics in Q4 2021 and has held it in 11 quarters since.
Citadel Advisors's Gain Therapeutics position peaked at $661K in Q3 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.